A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs RG 6146 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 03 Apr 2017 Planned End Date changed from 1 Aug 2017 to 31 Dec 2017.
- 03 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.
- 03 Apr 2017 Status changed from recruiting to active, no longer recruiting.